Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Grows By 122.2%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 2,000 shares, a growth of 122.2% from the February 28th total of 900 shares. Based on an average daily volume of 29,200 shares, the days-to-cover ratio is currently 0.1 days.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $0.03 on Friday. The stock’s fifty day moving average price is $0.04 and its two-hundred day moving average price is $0.05. SAB Biotherapeutics has a one year low of $0.01 and a one year high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.